| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021. doi: 10.3322/caac.21660. |
| [2] |
Halsted WS.The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June，1889，to January，1894[J]．Ann Surg，1894，20(5)：497-555.
|
| [3] |
Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer [J]. Ann Surg，1994，220(3): 391-398.
|
| [4] |
Fisher B, Montague E, Redmond C, et al. Findings from NSABP Protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. I. Radiation compliance and its relation to treatment outcome[J]. Cancer, 1980，46(1)：11-13.
|
| [5] |
No authors listed. Cancer research campaign (King’s/Cambridge) trial for early breast cancer. A detailed update at the tenth year. Cancer Research Campaign Working Party[J]. Lancet，1980，2(8185)：55-60.
|
| [6] |
Wetzig N, Gill PG, Espinoza D, et al. Sentinel-lymph-node-based management or routine axillary clearance? Five-year outcomes of the RACS sentinel node biopsy versus axillary clearance (SNAC) 1 trial: assessment and incidence of true lymphedema[J]. Ann Surg Oncol，2017，24(4)：1064-1070.
|
| [7] |
Canavese G, Bruzzi P, Catturich A, et al. Sentinel lymph node biopsy versus axillary dissection in node-negative early-stage breast cancer: 15-year follow-up update of a randomized clinical trial[J]. Ann Surg Oncol，2016，23(8)：2494-2500.
|
| [8] |
林武华，陈茜，周琦．乳腺癌术后上肢淋巴水肿的危险因素分析[J]．中华乳腺病杂志(电子版)，2020，14(3)：141-144.
|
| [9] |
Lyman GH, Somerfield MR, Bosserman LD, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update[J]. J Clin Oncol，2017，35(5)：561-564.
|
| [10] |
Wilke LG, Ballman KV, McCall LM, et al. Adherence to the National Quality Forum (NQF) breast cancer measures within cancer clinical trials: a review from ACOSOG Z0010[J]. Ann Surg Oncol，2010，17(8)：1989-1994.
|
| [11] |
Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial[J]. Lancet Oncol, 2010，11(10)：927-933.
|
| [12] |
Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial[J]. JAMA, 2017，318(10): 918-926.
|
| [13] |
Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial[J]. Lancet Oncol，2013，14(4)：297-305.
|
| [14] |
Galimberti V, Cole BF, Zurrida S, et al. IBCSG 23-01 randomised controlled trial comparing axillary dissection versus no axillary dissection in patients with sentinel node micrometastases [J]. Lancet Oncol，2013，14(4)：297-305.
|
| [15] |
Rubio IT. Sentinel lymph node biopsy after neoadjuvant treatment in breast cancer: work in progress[J]. Eur J Surg Oncol，2016，42(3)：326-332.
|
| [16] |
Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J]. J Clin Oncol，2005，23(12)：2694-2702.
|
| [17] |
van Deurzen CH, Vriens BE, Tjan-Heijnen VC, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review [J]. Eur J Cancer，2009，45(18)：3124-3130.
|
| [18] |
Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review[J]. JAMA Oncol，2017，3(4)：549-555.
|
| [19] |
Kang YJ, Han W, Park S, et al. Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy[J]. Breast Cancer Res Treat，2017，166(2)：473-480.
|
| [20] |
van Nijnatten TJ, Schipper RJ, Lobbes MB, et al. The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review and meta-analysis [J]. Eur J Surg Oncol，2015，41(10)：1278-1287.
|
| [21] |
Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial[J]. JAMA，2013，310(14)：1455-1461.
|
| [22] |
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol，2013，14(7)：609-618.
|
| [23] |
Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study [J]. J Clin Oncol，2015，33(3)：258-264.
|
| [24] |
Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial[J]. JAMA，2013，310(14)：1455-1461.
|
| [25] |
Desantis CE, Fedewa SA, Goding Sauer A, et al. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women[J]. CA Cancer J Clin，2016，66(1)：31-42.
|
| [26] |
Tran BNN, Ruan QZ, Epstein S, et al. Literacy analysis of National Comprehensive Cancer Network patient guidelines for the most common malignancies in the United States [J]. Cancer，2021，124(4)：769-774.
|
| [27] |
Gentilini O, Veronesi P, Botteri E, et al. Sentinel lymph node biopsy in multicentric breast cancer: five-year results in a large series from a single institution[J]. Ann Surg Oncol，2011，18(10)：2879-2884.
|
| [28] |
Barnwell JM, Arredondo MA, Kollmorgen D, et al. Sentinel node biopsy in breast cancer [J]. Ann Surg Oncol，1998，5(2)：126-130.
|
| [29] |
van la Parra RF, de Roos WK, Contant CM, et al. A prospective validation study of sentinel lymph node biopsy in multicentric breast cancer: SMMaC trial[J]. Eur J Surg Oncol，2014，40(10)：1250-1255.
|
| [30] |
Jagsi R, Hawley ST, Griffith KA, et al. Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer[J]. JAMA Surg，2017，152(3)：274-282.
|
| [31] |
Erdahl LM, Boughey JC, Hoskin TL, et al. Contralateral prophylactic mastectomy: factors predictive of occult malignancy or high-risk lesion and the impact of MRI and genetic testing[J]. Ann Surg Oncol，2016，23(1)：72-77.
|
| [32] |
Murphy BL, Glasgow AE, Keeney GL, et al. Selective use of sentinel lymph node surgery in patients undergoing prophylactic mastectomy using intraoperative pathology[J]. Ann Surg Oncol，2017，24(10)：3032-3037.
|
| [33] |
Nagaraja V, Edirimanne S, Eslick GD. Is sentinel lymph node biopsy necessary in patients undergoing prophylactic mastectomy? A systematic review and meta-analysis[J]. Breast J，2016，22(2)：158-165.
|
| [34] |
Cody HS 3rd. Reoperative sentinel lymph node biopsy: adding nuance to the management of locally recurrent breast cancer[J]. Ann Surg Oncol，2016，23(Suppl 5)：9012-9014.
|
| [35] |
Karanlik H, Ozgur I, Kilic B, et al. Sentinel lymph node biopsy and aberrant lymphatic drainage in recurrent breast cancer: Findings likely to change treatment decisions[J]. J Surg Oncol，2016，114(7)：796-802.
|
| [36] |
Poodt IGM, Vugts G, Maaskant-Braat AJG, et al. Risk of regional recurrence after negative repeat sentinel lymph node biopsy in patients with ipsilateral breast tumor recurrence[J]. Ann Surg Oncol，2018，25(5)：1312-1321.
|
| [37] |
Ahmed M, Baker R, Rubio IT. Meta-analysis of aberrant lymphatic drainage in recurrent breast cancer[J]. Br J Surg，2016，103(12)：1579-1588.
|
| [38] |
Ugras S, Matsen C, Eaton A, et al. Reoperative sentinel lymph node biopsy is feasible for locally recurrent breast cancer, but is it worthwhile？[J]. Ann Surg Oncol，2016，23(3)：744-748.
|
| [39] |
Biglia N, Bounous VE, Gallo M, et al. Feasibility and oncological safety of sentinel node biopsy in breast cancer patients with a local recurrence[J]. Breast，2018，41：8-13.
|
| [40] |
Houvenaeghel G, Quilichini O, Cohen M, et al. Sentinel lymph node biopsy validation for large tumors[J]. Int J Surg，2017，48：275-280.
|
| [41] |
国家肿瘤质控中心乳腺癌专家委员会，中国抗癌协会乳腺癌专业委员会，中国抗癌协会肿瘤药物临床研究专业委员会. 中国晚期乳腺癌规范诊疗指南(2020版)[J]. 中华肿瘤杂志，2020, 42(10)：781-797.
|
| [42] |
Gropper AB, Calvillo KZ, Dominici L, et al. Sentinel lymph node biopsy in pregnant women with breast cancer[J]. Ann Surg Oncol，2014，21(8)：2506-2511.
|
| [43] |
Giammarile F, Alazraki N, Aarsvold JN, et al. Response to comment by Aprile et al.: The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer[J]. Eur J Nucl Med Mol Imag，2014，41(6)：1259-1260.
|
| [44] |
Balaya V, Bonsang-Kitzis H, Ngo C, et al. What about sentinel lymph node biopsy for early breast cancer during pregnancy？[J]. J Gynecol Obstet Hum Reprod，2018，47(5)：205-207.
|
| [45] |
Desnyder SM, Mittendorf EA, Le-Petross C, et al. Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer[J]. Clin Breast Cancer，2018，18(1)：e73-e77.
|
| [46] |
Rosso KJ, Ueno NT, Woodward WA, et al. In response to "outcomes of patients with inflammatory breast cancer treated by breast conserving surgery" ：the argument against breast conservation and sentinel lymph node biopsy in IBC[J]. Breast Cancer Res Treat，2017，165(3)：779-781.
|